CRISPR screens of genome and customized sgRNA libraries in numerous disease models have identified novel oncogenic drivers and cancer dependencies (120, 121), synthetic lethal interactions with mutant RAS and BRAF (122, 123) and mechanisms of resistance to anti-cancer drugs (124). This evidence concerns the gene BRAF and cancer.